Chen Nan, Lee J Jack
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stat Methods Med Res. 2020 Sep;29(9):2717-2732. doi: 10.1177/0962280220910186. Epub 2020 Mar 17.
Master protocol designs are often proposed to improve the efficiency of drug development with multiple subgroups. In the basket trial design, different subgroups can have similar biological pathogenesis pathways. Hence, a target therapy can result in similar responses. A good information sharing strategy between different subgroups can potentially improve the efficiency of evaluating treatment efficacy. In traditional hierarchical models, based on the exchangeability assumption, all subgroups are placed into the same sharing pool for cross subgroup information sharing. However, due to the heterogeneity between subgroups, there can be large differences in drug efficacy. Under such cases, strong borrowing across all subgroups is not suitable and no borrowing can be inefficient, because the treatment effect is analyzed in each subgroup separately. We propose a Bayesian cluster hierarchical model (BCHM) to improve the operating characteristics of estimating the treatment effect in multiple subgroups in basket trials. Bayesian nonparametric method is applied to dynamically calculate the number of clusters by conducting a multiple cluster classification based on subgroup outcomes. A hierarchical model is used to compute the posterior probability of the treatment effect, with the borrowing strength determined by the Bayesian nonparametric clustering and the similarities between subgroups. We apply the BCHM to clinical trials with binary endpoints. For treatment effect estimation, the BCHM yields lower mean squared error values, when compared to the independent analyses. In scenarios with a heterogeneous treatment effect, the BCHM provides lower mean squared error values compared to traditional hierarchical models. In addition, we can construct a loss function to optimize the design parameters. BCHM provides a balanced approach and smart borrowing, which yields better results in assessing the treatment effect in different scenarios compared to other conventional methods.
主协议设计通常被提出来以提高针对多个亚组的药物开发效率。在篮式试验设计中,不同亚组可能具有相似的生物学发病机制途径。因此,一种靶向治疗可能会产生相似的反应。不同亚组之间良好的信息共享策略有可能提高评估治疗效果的效率。在传统的分层模型中,基于可交换性假设,所有亚组都被放入同一个共享池中进行跨亚组信息共享。然而,由于亚组之间的异质性,药物疗效可能存在很大差异。在这种情况下,对所有亚组进行强借用是不合适的,而不进行借用可能效率低下,因为是在每个亚组中分别分析治疗效果。我们提出一种贝叶斯聚类分层模型(BCHM),以改善篮式试验中多个亚组治疗效果估计的操作特性。应用贝叶斯非参数方法,通过基于亚组结果进行多聚类分类来动态计算聚类数量。使用分层模型来计算治疗效果的后验概率,借用强度由贝叶斯非参数聚类和亚组之间的相似性决定。我们将BCHM应用于具有二元终点的临床试验。对于治疗效果估计,与独立分析相比,BCHM产生的均方误差值更低。在治疗效果异质性的情况下,与传统分层模型相比,BCHM提供更低的均方误差值。此外,我们可以构建一个损失函数来优化设计参数。BCHM提供了一种平衡的方法和智能借用,与其他传统方法相比,在评估不同情况下的治疗效果时能产生更好的结果。